Bayer seeks EMA nod for Gadoquatrane Ruchika Sharma13 July 2025 11:30 AM ISTBerlin: Bayer has announced the submission of a marketing authorization application to the European Medicines Agency (EMA) for its...
Bayer gets UK nod for Lynkuet for moderate to severe vasomotor symptoms associated with menopause Ruchika Sharma11 July 2025 11:30 AM ISTBerlin: Bayer has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA, regulatory authority in the UK) for the...
Bayer Eylea 8 mg with extended 6-month treatment interval approved in EU for retinal diseases Ruchika Sharma29 Jun 2025 11:00 AM ISTBerlin: Bayer has received approval from the European Commission (EC) for a label extension in the European Union (EU) for Eylea 8 mg...
EMA Committee recommends marketing nod for Bayer advanced prostate cancer drug darolutamide Ruchika Sharma22 Jun 2025 1:00 PM ISTBerlin: Bayer has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has...
Bayer seeks USFDA nod for Gadoquatrane for contrast enhanced magnetic resonance imaging of CNS Ruchika Sharma17 Jun 2025 12:44 PM ISTBerlin: Bayer has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its...
Bayer, Broad Institute extend research collaboration to develop new cardiovascular therapies Ruchika Sharma11 Jun 2025 1:15 PM ISTBerlin: Bayer and the Broad Institute have extended their research collaboration of 10 years by an additional five years, to further advance...
Simultaneous treatment start with Finerenone and SGLT-2-inhibitor demonstrated positive data in patients with CKD associated with type 2 diabetes: Bayer Ruchika Sharma9 Jun 2025 10:00 AM ISTBerlin: Bayer has announced results of the Phase II CONFIDENCE study, demonstrating that simultaneous initiation of finerenone (Kerendia)...
Bayer arm secures exclusive worldwide rights to develop, commercialize clinical-stage WRN Inhibitor Ruchika Sharma8 Jun 2025 10:00 AM ISTSan Diego: Vividion Therapeutics, Inc., a clinical-stage biopharmaceutical company, and a wholly owned and independently operated subsidiary of...
Bayer Prostate Cancer Drug Nubeqa gains third regulatory win from USFDA Ruchika Sharma4 Jun 2025 2:59 PM ISTBerlin: Bayer has received approval from the U.S. Food and Drug Administration (FDA) for its oral androgen receptor inhibitor (ARi) Nubeqa...
Bayer Gets CDSCO Panel Nod To Conduct Phase 3 Trial for Finerenone Dr. Divya Colin31 May 2025 5:56 PM ISTNew Delhi: Bayer Pharmaceutical has received approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
Bayer Sevabertinib gets USFDA Priority Review status for HER2-mutant non-small cell lung cancer Ruchika Sharma29 May 2025 11:15 AM ISTBerlin: Bayer has received Priority Review status from the US Food and Drug Administration (FDA) for the investigational compound sevabertinib...
Bayer begins Phase I study with GIRK4 inhibitor for atrial fibrillation Ruchika Sharma25 May 2025 11:00 AM ISTBerlin: Bayer has announced initiation of a Phase I clinical trial with BAY 3670549, an investigational highly selective G-protein-coupled...
